A merger agreement between Shanghai Henlius Biotech (HKG:2696) and Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) has been terminated, a Wednesday Hong Kong bourse filing said.
Under the contract signed in June 2024, Fosun Pharma had agreed to acquire the shares it didn't already own in Henlius Biotech.
While the special resolution regarding the proposal was approved by the requisite majority at the firm's extraordinary general meeting, it was rejected at the H shareholders' class meeting.
Despite the deal falling through, Shanghai Fosun Pharmaceutical, which holds a 59.56% stake in Shanghai Henlius Biotech, will retain its controlling position in the latter.
Shares of Fosun Pharma were up over 1% in Hong Kong in recent trade, while Henlius Biotech fell over 4%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。